The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
Open accessAbstract
A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and safety for TMZ and PCB in adult patients who failed conventional treatment. Secondary objectives were to assess overall survival and health-related quality of life (HRQL). TMZ was given orally at 200 mg/m(2)/day or 150 mg/m(2)/day (prior chemotherapy) for 5 days, repeated every 28 days. PCB was given orally at 150 mg/m(2)/day or 125 mg/m(2)/day (prior chemotherapy) for 28 days, repeated every 56 days. HRQL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 [+3]) and the Brain Cancer Module 20 (BCM20). The 6-month PFS rate for patients who received TMZ was 21%, which met the protocol objective. The 6-month PFS rate for those who received PCB was 8% (P = 0.008, for the comparison). Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 weeks in the PCB group (P = 0.0063). The 6-month overall survival rate for TMZ patients was 60% vs. 44% for PCB patients (P = 0.019). Freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received. TMZ had an acceptable safety profile; most adverse events were mild or moderate in severity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The average historical PFS6 based on the above studies is 15.3 ± 3.8%”
From Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors (2007) · cites this paper as [25]
In the citing paper
“and the average historical TTP is 9.5 ± 1.6 weeks.”
From Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors (2007) · cites this paper as [25]
In the citing paper
“OS averaged 29.3 ± 6 weeks (see SI Table 2).”
From Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors (2007) · cites this paper as [25]
In the citing paper
“Efficacy analysis was performed for 10 recurrent GBM patients by comparing TTP, PFS6, and OS in recurrent GBM patients treated with the NovoTTF-100A device with the TTP, PFS6, and OS of recurrent GBM patients in a literature based historical control group (10, 25–28).”
From Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors (2007) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005 · cited 1×
“The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30 [+3]) (Aaronson et al, 1993; Osoba et al, 1997) and the Brain Cancer Module 20 (BCM20) (Osoba et al, 1996) questionnaires were used to measure HRQL. Questionnaires were administered on day 1…”
MethodSelf-citationJaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982 · cited 1×
“A 10-unit change on a 0–100 scale was deemed significant if it lasted for at least 8 weeks (Jaeschke et al, 1989; Juniper et al, 1994; King, 1996; Ware et al, 1998).”
Background(1994) · Medical Entomology and Zoology · Cited by 4,156
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016 · cited 1×
“Meaning of changes in HRQL scores was addressed by the method of Osoba et al (1998).”
MethodSelf-citationFayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 2,520
Determining a minimal important change in a disease-specific quality of life questionnaire
JUNIPER, E. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90036-1 · Cited by 1,824 · cited 1×
“A 10-unit change on a 0–100 scale was deemed significant if it lasted for at least 8 weeks (Jaeschke et al, 1989; Juniper et al, 1994; King, 1996; Ware et al, 1998).”
The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30
King, M. T. (1996) · Quality of Life Research · doi:10.1007/bf00439229 · Cited by 666
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)
Newlands, E. S., Blackledge, G. R. P., Slack, J., Rustin, G. J. S., Smith, D., Stuart, N., Quarterman, C., Hoffman, R., Stevens, M. F. G., Brampton, M., et al. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.57 · Cited by 488 · cited 3×
“TMZ has notable antitumour activity against recurrent GBM, recurrent anaplastic astrocytoma, and advanced malignant melanoma, and other refractory cancers (Newlands et al, 1992, 1996; O’Reilly et al, 1993; Bleehen et al, 1995; Bower et al, 1997).”
BackgroundResultMayer, A., Takimoto, M., Fritz, E., Schellander, G., Kofler, K., & Ludwig, H. (1993) · Cancer · doi:10.1002/1097-0142(19930415)71:8 · Cited by 407
Stevens, M. F. G., Hickman, J. A., Langdon, S. P., Chubb, D., Vickers, L. M., Stone, R., BAIG, G. U., Goddard, C. P., Gibson, N. W., & Slack, J. A. (1987) · PubMed · Cited by 387
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 928
Bevacizumab Use for Recurrent High-Grade Glioma at McGill University Hospital
Sahebjam, S., Garoufalis, E., Guiot, M., Muanza, T. M., Maestro, R. F. D., Petrecca, K., Sharma, R., & Kavan, P. (2013) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100013809 · Cited by 5
The Use of Temozolomide for Chemoradiation and Adjuvant Therapy of High-Grade Gliomas
Miller, J. J., & Reardon, D. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812100-9.00031-0 · Cited by 5
Kwon, Y. W., Moon, W., Park, M., Roh, H. G., Koh, Y. C., Song, S. W., & Choi, J. W. (2018) · Investigative Magnetic Resonance Imaging · doi:10.13104/imri.2018.22.3.158 · Cited by 5
“Combining radiotherapy with TMZ has been shown to improve prognosis and increase overall survival in high grade glioma patients (3-9).”
BackgroundNeurological Complications of Chemotherapy
Vargo, C. A., Ray, L. A., & Newton, H. B. (2017) · Springer eBooks · doi:10.1007/978-3-319-57901-6_15 · Cited by 5
Khalil, T., Lemaire, J., Dedieu, V., Donnarieix, D., Claise, B., Lapeyre, M., Kémény, J. L., Pereira, B., Thalami, A., Chazal, J., et al. (2013) · Europe PMC (PubMed Central) · Cited by 5
Advances in the therapy of high-grade glioma at relapse: pegylated liposomal doxorubicin
Hau, P., Dietrich, J., Fabel, K. S., & Bogdahn, U. (2002) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2.5.609 · Cited by 5
Newly Diagnosed High-Grade Gliomas
Giglio, P., & Villano, J. L. (2010) · Current Treatment Options in Neurology · doi:10.1007/s11940-010-0077-6 · Cited by 5
“Previously, Yung et al. [ 20 ,21] had demonstrated the benefit of TMZ in patients with WHO grade III astrocytomas and in patients with glioblastoma in first relapse.”
BackgroundNovedades terapéuticas del año 2000: los retos del médico y del gestor
Latorre, F. P. (2001) · Medicina Clínica · doi:10.1016/s0025-7753(01)71871-4 · Cited by 5
Cytotoxic and molecular chemotherapy for high-grade glioma: an emerging strategy for the future
Cavaliere, R., & Newton, H. B. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.6.749 · Cited by 5
“It has been estimated that 6-month progression-free and overall survival were ∼ 19 and 60%, respectively, with a median time to progression and overall survival of 10 weeks and 7 months, respectively [20-22].”
BackgroundThe role of bevacizumab in recurrent glioblastoma: new insights from randomized trials
Franceschi, E., & Brandes, A. A. (2015) · CNS Oncology · doi:10.2217/cns.15.7 · Cited by 5
Overview of pathology and treatment of primary brain tumours
Newton, H. B., & Fonkem, E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822835-7.00034-2 · Cited by 4
Cyclooxygenase-2 as a potential therapeutic target in the treatment of chemoresistant glioblastomas
Skossyrskiy, V. S., Kurdina, N. A., Kuzovkova, V. S., Boot, M. S., Zelenchenkova, P. I., Popova, E. O., Sevyan, N. V., Mitrofanov, A. A., Прозоренко, Е. В., Sekacheva, M. I., et al. (2025) · Medical Oncology · doi:10.1007/s12032-025-03000-z · Cited by 4
Yang, P., Zhang, C., Cai, J., You, G., Wang, Y., Qiu, X., Li, S., Wu, C., Yao, K., Li, W., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11756 · Cited by 4
“However, the effective response of glioblastomas ranged between 5% and 8%.[18, 19] The role of TMZ chemotherapy was undefined [20] until the EORTC 26981 trial was published.”
BackgroundShi, D., Zhong, W., Liu, D., Sun, X., Hao, S., Yang, Y., Ao, L., Zhou, J., Xia, Y., Zhou, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.932938 · Cited by 4
Chemotherapy for Glioblastoma: Past, Present, and Future
Giglio, P. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0410-2_10 · Cited by 4
López‐Ginés, C., Gil‐Benso, R., Monleón, D., Gonzalez-Darder, J. M., & Cerdá‐Nicolás, M. (2011) · InTech eBooks · doi:10.5772/21697 · Cited by 4
“Likewise, chemotherapy strategies active in other tumors, have shown a relative efficacy in glioblastoma (Walker et al.., 1978, Walker et al., 1980, Yung et al., 2000; Balañá et al., 2004).”
BackgroundAntivascular Endothelial Growth Factor Antibody for Treatment of Glioblastoma Multiforme
Hanson, J. A., Hsu, F. P. K., Jacob, A. T., Bota, D. A., & Alexandru, D. (2013) · The Permanente Journal · doi:10.7812/tpp/13-081 · Cited by 4
“Cohen,19 2009 Phase 2 Irinotecan Adjuvant, recurrence 85 54 (23-78) > 70 36.”
InfluentialSupratentorial High-Grade Gliomas
Tarapore, P. E., Banerjee, A., & Gupta, N. M. (2010) · Springer eBooks · doi:10.1007/978-3-642-02874-8_26 · Cited by 4
Kakkar, A., Kumar, A., Jha, P., Goyal, N., Mallick, S., Sharma, M. C., Suri, A., Singh, M., Kale, S. S., Julka, P. K., et al. (2014) · Neuropathology · doi:10.1111/neup.12107 · Cited by 4
Novel therapeutics in adult malignant brain gliomas
Reni, M., Mazza, E. A., Tosoni, A., & Brandes, A. A. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.643 · Cited by 4
“As PFS-6 with temozolomide alone was 18 – 24% [131-133], these findings seem to be promising.”
BackgroundDesigning clinical trials for brain tumors: The next generation
Gilbert, M. R. (2007) · Current Oncology Reports · doi:10.1007/bf02951425 · Cited by 4
“As described by Robins et al. in this issue, recognition of this problem has led to the development of alternative endpoints, such as 6-month progression-free survival (PFS), in clinical trials evaluating treatment of recurrent glioblastoma [ 19 ].”
BackgroundChimiothérapie et traitements ciblés des glioblastomes
Chinot, O. L., Soulier, P., & Frénay, M. (2010) · Neurochirurgie · doi:10.1016/j.neuchi.2010.07.013 · Cited by 4
Carboplatin and oral cyclophosphamide combination after temozolomide failure in malignant gliomas
Yaman, E., Buyukberber, S., Üner, A., Çoşkun, U., Yamaç, D., Öztürk, B., Ali Osman, K. A. Y. A., & Yıldız, R. (2008) · Tumori Journal · doi:10.1177/030089160809400505 · Cited by 4
Nanomedicine and Brain Tumors Treatment
Caruso, G., Caffo, M., Raudino, G., Tomasello, C., Alafaci, C., & Tomasello, F. F. (2012) · Springer eBooks · doi:10.1007/978-3-642-29265-1_6 · Cited by 4
Roberge, D., & Souhami, L. (2008) · Springer eBooks · doi:10.1007/978-0-387-71070-9_17 · Cited by 4
Valeriani, M., Ferretti, A., Franzese, P., & Tombolini, V. (2006) · PubMed · Cited by 4
Greanya, E., Taylor, S., BscPharm, F. H., Barnett, J., & Thiessen, B. A. (2004) · Journal of Oncology Pharmacy Practice · doi:10.1191/1078155204jp138oa · Cited by 4
Cilengitide: Does It Really Represent a New Targeted Therapy for Recurrent Glioblastoma?
Chamberlain, M. C. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.5871 · Cited by 4
Future Trends in the Treatment of Brain Tumors
Basso, U., Longo, F., & Mansueto, G. (2001) · Tumori Journal · doi:10.1177/030089160108700325 · Cited by 4
Watanabe, S., Maeda, M., Sugii, N., Yamada, M., Arakawa, Y., Nakamura, K., Hashimoto, K., & Ishikawa, E. (2025) · Cancers · doi:10.3390/cancers17050855 · Cited by 3
“The settings of phase II clinical trials of products previously approved for glioblastoma included a high number of pharmaceutical drugs, numerous studies targeting recurrent glioblastoma, predominantly open-label and uncontrolled studies, with PFS or OS rates frequently used as endpoints [18–22].”
Combination Cancer Therapy and Reference Models for Assessing Drug Synergy in Glioblastoma
Sinyavskiy, S., Chmelyuk, N. S., Travnikova, D. Y., Belousov, V. V., & Abakumova, T. O. (2025) · Current Oncology · doi:10.3390/curroncol33010019 · Cited by 3
“These findings suggest that adding cisplatin to TMZ may improve short-term disease outcomes and survival, although cross-trial comparisons should be interpreted cautiously due to potential differences in patient populations, dosing, and study design [32,44–46].”
ADULT OPTIC NERVE GLIOMA PRESENTING AS CENTRAL RETINAL VEIN OCCLUSION
Yatziv, Y., Bukstein, F., Segev, Y., & Kesler, A. (2007) · Retinal Cases & Brief Reports · doi:10.1097/01.icb.0000256943.65200.24 · Cited by 3
Guide de prescription et de bon usage du témozolomide dans les tumeurs cérébrales
Tilleul, P. R., Brignone, M., Hassani, Y., Taillandier, L., Taillibert, S., Cartalat‐Carel, S., Borget, I., & Chinot, O. L. (2009) · Bulletin du Cancer · doi:10.1684/bdc.2009.0865 · Cited by 3
Donor-Transmitted Melanoma: Is It Still Bothering Us?
Abdullayeva, L. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00740-0 · Cited by 3
Quality of life in glioblastoma after the introduction of temozolomide: a systematic review
Dias, T. A. O., Couto, D. S., & Cardoso, E. J. R. (2022) · Research Society and Development · doi:10.33448/rsd-v11i15.37205 · Cited by 3
Bao, H., Ai, S., Wang, G., Yi, L., Lai, J., Wang, S., Lv, Z., Li, C., Liu, Q., Zhao, X., et al. (2023) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2023.108103 · Cited by 3
African medicinal plants and their constituents can fight glioblastoma and its drug resistance
Mbaveng, A. T., & Kuete, V. (2024) · Advances in botanical research · doi:10.1016/bs.abr.2023.12.009 · Cited by 3
Tilleul, P. R., Brignone, M., Hassani, Y., Labrande, C., Pédeboscq, S., Gensollen, S., Lahille, B., Exinger, D., Bertholle, V., Billard, M., et al. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3233 · Cited by 3
Overview of Epidemiology, Pathology, and Treatment of Primary Brain Tumors
Newton, H. B., & Otero, J. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417043-8.00002-x · Cited by 3
Zentrales Nervensystem und Sinnesorgane
Engenhart‐Cabillic, R., Groß, M. W., Henzel, M., Bois, A. Z.-D., Milker-Zabel, S., & Rades, D. (2013) · Strahlentherapie · doi:10.1007/978-3-540-88305-0_16 · Cited by 3
Koch, D., & Wick, W. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-9019-7 · Cited by 3
“Moderate activity of temozolomide (TMZ) dosed at 150–200 mg/m(2) for five days every five weeks in chemoresistant cancers [1] has provoked the clinical evaluation of a series of alternative dose-intensified TMZ schedules.”
BackgroundIntroduction: future trends in the treatment of brain tumors
Brandes, A. A. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.11.021 · Cited by 3
Phase I study of temozolomide and lomustine in the treatment of high grade malignant glioma
Tafuto, S. (2006) · Frontiers in bioscience · doi:10.2741/1814 · Cited by 3
Application of Decision-Analytic Modelling in Health Economic Evaluations
Martikainen, J. A. (2008) · Cited by 3
Overview of Pathology and Treatment of Primary Brain Tumors
Newton, H. B. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800945-1.00002-1 · Cited by 3
Anvari, K., Bahadorkhan, G., Nekooi, S., Taghizadeh, A., Kheradmand, H., Nowferesti, G., Aledavood, S. A., Tousi, M. S., Mashhadinejad, H., Anaraki, S. Z., et al. (2009) · Cited by 3
State-of-the-art Therapy for Glioblastoma Multiforme
Friedman, H. S. (2007) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2007.00.01.16 · Cited by 3
“Although the registration trial for patients with first-relapse GBM demonstrated a near tripling of the six-month progression-free survival, concerns voiced by the US Food and Drug Administration (FDA) regarding this as a legitimate end-point prevented the approval of temozolomide for this indication.(7) However, the…”
BackgroundSelf-citationParney, I. F., & Prados, M. D. (2005) · Textbook of Neuro-Oncology · doi:10.1016/b978-0-7216-8148-1.50014-0 · Cited by 3
Self-citationSilvani, A., Lamperti, E., Gaviani, P., Eoli, M., Fiumani, A., Salmaggi, A., Falcone, C., Filippini, G., Botturi, A., & Boiardi, A. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9539-z · Cited by 3
Evidence-based Standard Care of Malignant Glioma
Shinoda, J., Yano, H., & Sakai, N. (2004) · Japanese Journal of Neurosurgery · doi:10.7887/jcns.13.3 · Cited by 3
Lassman, A. B., Matceyevsky, D., & Corn, B. W. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24098-7.00027-7 · Cited by 2
Грецких, К. В., & Токарев, А. С. (2021) · Russian journal of neurosurgery · doi:10.17650/1683-3295-2021-23-1-124-134 · Cited by 2
Intranasal Delivery of Nanoparticles
Friedrich, R. P., Cicha, I., Tietze, R., Unterweger, H., Lyer, S., Janko, C., & Alexiou, C. (2022) · Nanomedicine · doi:10.2217/nnm-2021-0418 · Cited by 2
Mason, W. P., Mirimanoff, R. O., & Stupp, R. (2006) · Progress in Neurotherapeutics and Neuropsychopharmacology · doi:10.1017/s1748232105000054 · Cited by 2
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma
The Singapore Cancer Network (SCAN) Neuro-Oncology Workgroup (2015) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v44n10p463 · Cited by 2
Malignant gastrointestinal neuroectodermal tumor: a case report and literature review
Su, D., Yang, H., Zhao, M., Zhou, H., Wu, J., Zhao, Z., Zhong, J., Xue, Q., Hong, Y., Sun, J., et al. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001400 · Cited by 2
Howarth, A., Simms, C., Kerai, N., Allen, O., Mihajluk, K., Madureira, P. A., Sokratous, G., Cragg, S. M., Lee, S. Y., Morley, A. D., et al. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.07.007 · Cited by 2
“The current standard chemotherapeutic for aHGG treatment is the DNA alkylating drug temozolomide (Temodal) (TMZ) [6,7].”
BackgroundTsai, H., Wei, K., Chen, P., Huang, C.-Y., Chen, K., Lin, Y.-J., Cheng, H.-W., Huang, C., & Wang, H. (2021) · NeuroMolecular Medicine · doi:10.1007/s12017-021-08667-x · Cited by 2
Molecular Mechanisms of Pathogenesis in Glioblastoma and Current Therapeutic Strategies
Welsh, C. T. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0410-2_4 · Cited by 2
Rodríguez, R., Lombardo, K., Roldán, G. B., Silvera, J., & Lagomarsino, R. (2012) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 2
Hernández, J. E., Magdalena, J. H., Feijoó, A. F., & de la Blanca, E. B. P. (2003) · Revista de Oncología · doi:10.1007/bf02712839 · Cited by 2
Apoptotic Events in Glioma Activate Metalloproteinases and Enhance Invasiveness
Magro, A. M. (2013) · InTech eBooks · doi:10.5772/52359 · Cited by 2
Terasaki (2009) · Molecular Medicine Reports · doi:10.3892/mmr_00000115 · Cited by 2
A Changing Paradigm of Glioma Biology
Shapiro, W. R., & Shapiro, J. R. (2006) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2006.09.010 · Cited by 2
Self-citationLong-term survival with unmethylated MGMT glioblastoma multiforme
Savva-Bordalo, J., Soares, A., Rocha, P., Jácome, M., Maurício, J., & Ferreira, R. (2011) · International Journal of Case Reports and Images · doi:10.5348/ijcri-2011-07-43-cr-3 · Cited by 2
“At first recurrence the patient was treated with TMZ alone, which has been shown to be successful in patients with recurrence following primary treatment with surgery, RT and adjuvant nitrosourea chemotherapy [8-11].”
MethodJohnson, D. R., Ashman, J. B., Brown, P. D., Lachance, D. H., & Buckner, J. C. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-166-0_6 · Cited by 2
Clinical trials in neuro-oncology
Junck, L. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52138-5.00028-1 · Cited by 2
Tini, P., Miracco, C., Toscano, M., Palumbo, S., Comincini, S., Gravina, G. L., & Pirtoli, L. (2016) · Current clinical pathology · doi:10.1007/978-3-319-28305-0_7 · Cited by 2
Gilbert, M. R., Aldape, K. D., & Sorensen, A. G. (2009) · Cited by 2
Advances in Treatment Options for High-grade Glioma—Current Status and Future Perspectives
Merrell, R. T., Lee, E. Q., Wen, P. Y., Fellow, N.-O., Neuro-oncologist, & Neuro-oncologist (2010) · touchREVIEWS in Neurology · doi:10.17925/usn.2010.06.01.55 · Cited by 2
Belyaev, A. Y., Kobyakov, G. L., Shmakov, P. N., Efremov, K. V., Pronin, I., & Usachev, D. Y. (2023) · Burdenko s Journal of Neurosurgery · doi:10.17116/neiro20238704146 · Cited by 2
Levin, V. A. (2015) · PubMed · Cited by 2
Self-citationLong-lasting partial regression of glioblastoma multiforme achieved by edotecarin: case report.
Vrdoljak, E., Boban, M., Saratlija-Novaković, Ž., & Jović, J. (2006) · PubMed Central · Cited by 2
Avances en el tratamiento del glioblastoma multiforme
Jaramillo, S., Osorio-Cardona, W., & Espitia, J. C. (2010) · Universitas Médica · doi:10.11144/javeriana.umed51-2.atgm · Cited by 2
“Estos dos resultados han sido estudiados, ya que se encontró recientemente que en oligodendrogliomas con deleción 1p/19q hay una asociación de 80% con la metilación del gen promotor de O6 metilguanina ADN metiltransferasa, lo cual podría llevar a generar nuevos protocolos para el tratamiento y la asociación de terapia…”
BackgroundIntrakranielle und spinale Tumoren
Schlegel, U. S. (2005) · Elsevier eBooks · doi:10.1016/b978-343723390-6.50039-5 · Cited by 2
Brain tumors – other treatment modalities
Peyrl, A., Frischer, J. M., Hainfellner, J. A., Preusser, M., Dieckmann, K. U., & Marosi, C. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802395-2.00034-1 · Cited by 3
Desjardins, A., & Sampson, J. H. (2011) · Journal of neurosurgery · doi:10.3171/2011.8.jns111107 · Cited by 2
Abrey, L. E. (2005) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-005-0043-y · Cited by 2
“Initially approved in the United States for the treatment of recurrent anaplastic astrocytoma, temozolomide has been observed to have activity in the adjuvant treatment of glioblastoma multiforme [1, 2 ].”
BackgroundO 4-benzylfolic acid inactivates O 6-alkylguanine-DNA alkyltransferase in brain tumor cell lines
Johnson, S. P., Kamen, B. A., Bigner, D. D., & Friedman, H. S. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0435-6 · Cited by 2
“After an initial observation that patients with high grade gliomas responded to temozolomide [19, 20], a phase 2 trial of temozolomide prior to radiation therapy in the treatment of newly diagnosed high grade glioma demonstrated striking activity [10], a result that has subsequently been conWrmed in both recurrent [32…”
BackgroundSelf-citationTemozolomide treatment in glioma Experiences in two university hospitals in finland
Mäenpää, H. O., Aaltonen, K., Mäntylä, R., & Minn, H. R. I. (2004) · Acta Oncologica · doi:10.1080/02841860410015271 · Cited by 2
Somer, R. A., & Langer, C. J. (2005) · Cancer Investigation · doi:10.1081/cnv-200050449 · Cited by 2
Management of recurrent gliomas and meningiomas
Hou, L. C., & Harsh, G. R. (2011) · Elsevier eBooks · doi:10.1016/b978-0-443-06967-3.00019-3 · Cited by 2
Rhee, J. Y., Miller, P., Finnemore, A., Tentor, Z., Durieux, B. N., Ardeljan, L., Lindvall, C. J., Jones, K. F., & Sager, Z. S. (2026) · Neuro-Oncology Practice · doi:10.1093/nop/npag009 · Cited by 1
Anti-Angiogenic Therapy for Malignant Glioma: Insights and Future Directions
Province, P., Han, X., Burt, L., & Hassan, M. (2011) · InTech eBooks · doi:10.5772/23021 · Cited by 1
Stereotactic Radiosurgery and Radiotherapy in the Management of High-Grade Gliomas
Roberge, D., & Souhami, L. (2015) · Springer eBooks · doi:10.1007/978-1-4614-8363-2_17 · Cited by 1
A Review of the Treatment Options in Recurrent Glioblastoma: Focus on Bevacizumab
Yong, R. L. M. (2011) · Clinical Medicine Reviews in Oncology · doi:10.4137/cmro.s1528 · Cited by 1
Guiu, S., Taillibert, S., Chinot, O. L., Taillandier, L., Honnorat, J., Dietrich, P., Maire, J. P., Guillamo, J., Guiu, B., Catry‐Thomas, I., et al. (2009) · Revue Neurologique · doi:10.1016/s0035-3787(09)70008-6 · Cited by 1
Weller, M., Tonn, J. C., Ernemann, U., Wiestler, O. D., & BAMBERG, M. (2009) · best practice onkologie · doi:10.1007/s11654-008-0108-x · Cited by 1
Mason, W. P., Mirimanoff, R. O., & Stupp, R. (2006) · Cambridge University Press eBooks · doi:10.1017/cbo9780511663529.005 · Cited by 1
Effectiveness of Interferon-Beta Therapy for Recurrent Glioblastoma: A Case Report
Utsuki, S., Oka, H., Miyajima, Y., Sato, K., Shimizu, S., Suzuki, S., & Fujii, K. (2011) · Tumori Journal · doi:10.1177/030089161109700121 · Cited by 1
Treatment of High-Grade Gliomas in Adults
Drappatz, J., Norden, A. D., & Wen, P. Y. (2009) · Springer eBooks · doi:10.1007/978-3-642-00475-9_16 · Cited by 1
“Other investigational therapies for high-grade gliomas include chemotherapeutic agents with improved penetration across the blood-tumor barrier (Regina et al. 2008), peptide and dendritic cell vaccines (Luptrawan et al. 2008; Yamanaka 2008 ), and gene therapy (Fulci and Chiocca 2007).”
BackgroundAltered GABA function in Major Depression
French, B. J., Seney, M. L., & Sibille, E. L. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1056-4_13 · Cited by 1
Bogdahn, U. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor047 · Cited by 1
Shawky, H., Ah, A. H., Galal, S., Zakaria, F., & El-Shorbagy, D. (2009) · PubMed · Cited by 1
Glioblastoma: Temozolomide-Based Chemotherapy
Beier, D., & Beier, C. P. (2010) · Springer eBooks · doi:10.1007/978-94-007-0344-5_25 · Cited by 1
Diagnostik und Therapie des Glioblastoms
Weller, M., Tonn, J. C., Ernemann, U., Wiestler, O. D., & BAMBERG, M. (2006) · Der Onkologe · doi:10.1007/s00761-006-1054-2 · Cited by 1
“BCNU steht auch in Form der Gliadel®Wafer für die lokoregionäre Applikation zur Verfügung.”
BackgroundInfluentialRadiation Tolerance of Normal Brain: QUANTEC 2010 and Beyond
Felice, F. D., Tombolini, V., Buglione, M., Musio, D., Triggiani, L., & Magrini, S. M. (2016) · Current clinical pathology · doi:10.1007/978-3-319-28305-0_8 · Cited by 1
Clinical trials and chemotherapy
Pouratian, N., Cifarelli, C. P., Shaffrey, M. E., & Schiff, D. (2011) · Elsevier eBooks · doi:10.1016/b978-0-443-06967-3.00016-8 · Cited by 1
Targeted Therapies in Brain Tumours: An Overview
Crilly, S. M., & O’Halloran, P. J. (2016) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-46505-0_1 · Cited by 1
Benefits afforded by combined temozolomide, radiation and stem cell strategy for glioma therapy
Li, B., Wang, F., & Hai, J. (2017) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v16i6.16 · Cited by 1
“Temozolomide (an alkylating agent) has good oral bioavailability and is well tolerated, so it is widely used to treat glioblastoma [9,10].”
Background
Metadata
- Authors
- Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., Glantz, M., Greenberg, H., Selker, R. G., Vick, N. A., Rampling, R., Friedman, H., Phillips, P., Bruner, J., Yue, N., Osoba, D., Zaknoen, S., & Levin, V. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Emory University (US)
- University of Mississippi Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
- University of California, San Francisco (US)
- Royal Marsden NHS Foundation Trust (GB)
- University of Washington (US)
- University of Iowa Hospitals and Clinics (US)
- Barrow Neurological Institute (US)
- Memorial Hospital of Rhode Island (US)
- University of Michigan (US)
- Western Pennsylvania Hospital (US)
- Evanston Hospital (US)
- Beatson West of Scotland Cancer Centre (GB)
- Duke University (US)
- BC Cancer Agency (CA)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- British Journal of Cancer
- Published
- 2000-09
- Volume
- 83
- Issue
- 5
- Pages
- 588-593
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2363506
- OpenAlex
- W1977392502
- Cited by
- 929
- References
- 27
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 8 · 2023: 23 · 2022: 19 · 2021: 21 · 2020: 21 · 2019: 20 · 2018: 27 · 2017: 23 · 2016: 31 · 2015: 32 · 2014: 33 · 2013: 38 · 2012: 50
- FWCI
- 21.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Keywords
- temozolomide, procarbazine, glioblastoma, first relapse, progression-free survival, overall survival, health-related quality of life, alkylating agents, oral chemotherapy, treatment safety
- MeSH terms
- Temozolomide, Adult, Aged, Antineoplastic Agents, Brain Neoplasms, Dacarbazine, Female, Glioblastoma, Humans, Male, Middle Aged, Procarbazine, Prognosis, Quality of Life, Recurrence, Time Factors, Gliosarcoma, Disease-Free Survival, Antineoplastic Agents, Alkylating
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
